Every article, report, and earnings note where TEM appears.
Tempus AI is scaling quickly in oncology diagnostics and data licensing, but losses, negative free cash flow, and leverage keep the stock in Hold territory.
Tempus AI, Inc. (TEM) climbs after a positive Merck-Moderna melanoma result sparked fresh enthusiasm for precision oncology and MRD testing. The rally also follows solid Q2 results and renewed attention on Tempus’ Personalis acquisition, though the stock remains volatile and richly valued.
TEM’s 24.1% headline-free surge looks like investors repricing a real profitability inflection, not chasing an empty AI story. Q2 revenue growth, a guidance raise and a path to positive cash flow give the rally a fundamental anchor despite expensive valuation.
TEM's sharp rally is absorbing Personalis dilution risk because the growth engine is getting harder for the market to ignore. Revenue growth, MRD adoption and repeated earnings beats give the bull case more weight than the deal's near-term optics.
TEM's 13% surge is running ahead of an unprofitable business and a $1.5 billion Personalis deal that adds scale before it adds clean earnings. Strong revenue growth is real, but dilution, cash needs, and insider selling make this rally one to fade rather than chase.
Tempus AI is getting sold on supposedly bullish news because the market still does not trust growth financed with more paper. The Personalis deal, fresh convert dilution, and persistent losses are colliding with a stock that was never priced for execution mistakes.
These seven AI biotech stocks span diagnostics, software, platform discovery, and commercial therapeutics, ranked by investment quality for June 2026.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate TEM ReportCancel anytime